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Abstract
Health care claims data refer to information generated from interactions within
health systems. They have been used in health services research for decades to assess
effectiveness of interventions, determine the quality of medical care, predict disease
prognosis, and monitor population health. While claims data are relatively cheap and
ubiquitous, they are high-dimensional, sparse, and noisy, typically requiring dimension
reduction. In health services research, the most common data reduction strategy in-
volves use of a comorbidity index – a single number summary reflecting overall patient
health. We discuss Bayesian regularization strategies and a novel hierarchical prior
distribution as better options for dimension reduction in claims data. The specifica-
tions are designed to work with a large number of codes while controlling variance by
shrinking coefficients towards zero or towards a group-level mean. A comparison of
drug-eluting to bare-metal coronary stents illustrates approaches. In our application,
regularization and a hierarchical prior improved over comorbidity scores in terms of
prediction and causal inference, as evidenced by out-of-sample fit and the ability to
meet falsifiability endpoints.
Keywords: Bayesian methods; comorbidity scores; propensity score weighting; regular-
ization; coronary stent.
1 Introduction
Health services researchers focus on assessing the effectiveness of treatments and policy
interventions, characterizing the quality of medical care delivered to specific populations,
and developing payment systems, with the goal of improving health outcomes. A funda-
mental data source used in health services research is administrative billing claims data.
Claims data refer to a wide range of administrative databases capturing health care uti-
lization information for reimbursement purposes and are generated by routine interactions
between patients, the health system, and insurance providers [12]. This type of data stands
in contrast to other formats, like clinical registry data, which are prospectively collected
for the explicit purpose of later analysis and are of considerably higher quality [6][27][12].
However claims data have many desirable features: they are generated during the normal
work flow and thus avoid additional effort and expense; they provide an accounting of de-
nominator populations to ensure rates are well-defined; and they have standard definitions
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to help with consistency of the information collected across the nation and around the
world.
In this article, we focus on claims data comprised of alpha-numeric codes for conditions
from the International Classification of Diseases (9th Clinical Modification, [ICD-9]) system
[9]. The structure of ICD-9 codes is a tree-like hierarchy with each code constructed as
a binary variable. The codes contain 3-5 alpha-numeric strings where the first 3 charac-
ters define a group of diagnoses (or procedures) and the additional two characters provide
further specificity. The ICD-9 codes include approximately 17,000 distinct codes at level
5, many of which represent rare conditions that are unlikely to be observed in any finite
population. Coding practices can also vary across health delivery settings such that codes
are noisy representations of true conditions. A revision of ICD-9 codes (ICD-10) took effect
in October 2015 in the United States, and contains approximately 68,000 codes having a
similar hierarchical structure to the ICD-9 system. Thus, while claims data are relatively
cheap and ubiquitous, they are high-dimensional, sparse, and noisy. Consequently, some
form of dimension reduction for inference is required.
Researchers have proposed a variety of dimension reduction approaches when using
claims data. The most common strategies either use clinical expertise to select a small set
of codes and include separate binary indicators for each discrete diagnosis or procedure,
or implement standard variable selection approaches such as step-wise regression. Because
these approaches may omit important variables, inclusion of a summary measure, called a
comorbidity index or score, helps with adjusting for other health features [29]. Two of the
most frequently used comorbidity indices include the Charlson and the Elixhauser [7][8].
These indices were constructed by selecting and validating ICD-9 codes based on a combi-
nation of clinical expertise and statistical analysis. The Elixhauser index has been shown to
predict long-term clinical outcomes better than the Charlson index [29]. Both indices may
be implemented as a set of dummy variables indicating the presence of groups of conditions
(e.g. hypertension, diabetes, etc) if feasible or as a single continuous variable constructed
from a weighted sum of the individual condition groups [7][39]. A recent paper by Gilbert et
al argued that using a comorbidity index with fixed historical weights is as good as includ-
ing individual claims coefficients in causal survival analysis [11]. However the assumptions
associated with the strategy are rather strong, inferences may be compromised by ignoring
uncertainty from the estimation of the weights, and the findings do not translate to other
approaches like propensity score analyses or logistic regression for mortality prediction.
Our point of departure from typical approaches is to consider the dimension reduction
task as one of regularization. Fundamentally some outside information, typically an as-
sumption that some of the conditions have little or no effect on the outcome of interest,
must be incorporated when the number of variables available exceeds the capacity of the
data for appropriately precise estimation.
We note that other sophisticated methods have been developed to use high-dimensional
claims data for various analysis goals. Syed et al proposed using a support vector machine
to enhance risk prediction using current procedural terminology codes [36]. Perotte et al
proposed exploiting the hierarchical nature of ICD-9 codes using a support vector machine
for diagnosis code assignment [20]. Singh used the group lasso to improve outcome pre-
diction by accounting for the ICD-9 hierarchy in a frequentist setting [30]. In the causal
inference domain, Schneeweiss et al developed a frequentist algorithm to select claims con-
founders based on their prevalence and univariate associations with both treatment and
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outcome [28].
Our work is motivated by determining the comparative effectiveness of coronary stents
once released into the U.S. market. Stents are small scaffolds placed into the heart via a
percutaneous coronary intervention (PCI) in order to treat arteries blocked by plaque and
keep them clear and open. Drug-eluting stents (DESs) are coated in a drug designed to
keep plaque from re-forming, while bare-metal stents (BMSs) have no such coating. Clin-
ical trials have consistently shown that DESs are efficacious as they reduce the need for
target vessel revascularization (TVR), i.e. follow-up procedures in the same artery, but
have no benefit on survival [2][34]. However, DESs necessitate adherence to prolonged
dual-antiplatelet therapies to prevent rare but fatal stent thrombosis. Several patient char-
acteristics such as age, comorbidity, and socio-economic factors may impact adherence to
dual-antiplatelet therapy, and thus such patients are likely to be implanted with BMSs
[33]. Because these characteristics also tend to increase the risk of adverse outcomes, ob-
served differences in average outcomes between BMS and DES treated patient groups are
heavily confounded. Even after statistical adjustments various observational analyses have
generally found that DES provides a survival benefit in usual care populations [14][37]. Al-
though there has historically been speculation that this benefit was real but not observed
in randomized trial populations, a recent quasi-randomization analysis and the results of a
large pragmatic clinical trial make a strong case that any observed survival benefit is due
to residual confounding [42][2]. As a result, it remains an open challenge for observational
causal inference to accurately estimate the effects of DES versus BMS using observational
data. It may be possible to achieve better results by including claims data in some form.
While we utilize a Bayesian propensity score framework, the ideas apply to other tech-
niques such as frequentist propensity scores or Bayesian outcome modeling. A Bayesian
approach is particularly well aligned with high-dimensional inference with claims data, as it
provides a number of intuitive tools for model building and incorporates all major sources
of uncertainty, which may ultimately lead to better inferential performance [31]. Our focus
is on improving over a typical analysis using comorbidity indices and to this end we make
three interdependent arguments: (1) administrative claims data can help analysts meet the
ignorability assumption in observational studies, but standard comorbidity indices may be
insufficient; (2) using a considerably larger and more granular set of claims data may lead
to better results compared with a comorbidity index; and (3) regularization techniques are
very useful for controlling variance when using a high-dimensional set of claims data. Com-
bining these principles, we find that employing high-dimensional claims data with Bayesian
regularization techniques leads to significant improvement over a comorbidity index in terms
of treatment model fit and causal inference.
In section 2 we briefly remind the reader the necessary assumptions for causal inference
with observational data and review propensity score approaches. Our proposed methods
are presented in detail in section 3. Section 4 illustrates various strategies for dimension
reduction by revisiting the DES vs BMS problem. We conclude with a discussion of the ad-
vantages of regularization over comorbidity indices for causal inference, as well as potential
improvements and modifications for future research.
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2 Causal Inference and Propensity Scores
2.1 Causal Inference
Causal inference involves various assumptions, three of which include stable unit treatment
value assumption (SUTVA), positivity, and treatment assignment ignorability. We focus
on binary treatments where a new treatment is compared to a standard treatment. In this
setting, SUTVA implies that treatment does not vary within treatment groups and that
the treatment received by one subject does not affect the outcomes of another. Positivity
requires that every subject has a chance of receiving the new treatment and we assume
that this probability is bounded away from 0 and 1. Positivity can be empirically tested in
that blatant violations are apparent by examination or modeling of the data. Propensity
scores help facilitate assessing the positivity assumption [21]. Finally, ignorability assumes
that potential outcomes are independent of treatment assignment [24]. In observational
designs, investigators must adjust for confounders, variables that affect both treatment
assignment and outcome, to uncover the causal effect of a particular treatment. This task
is among the most challenging in observational causal inference and has inspired many
attempts to define methods, either statistical or expertise driven, to select confounders for
adjustment [3][28][31]. High-dimensional datasets may provide important variables that
help investigators meet the ignorability assumption. In particular, health care claims data
provide an exciting source of potential confounders, presenting a host of opportunities as
well as challenges for researchers.
2.2 Propensity Scores
Propensity scores are the probabilities of receiving the new treatment relative to the stan-
dard treatment. They are a commonly used tool for observational causal inference. One
particularly important feature involves facilitating an outcome free analysis in that they
separate outcome modeling from treatment modeling which can help to maintain objec-
tivity [25]. This feature is often a requirement by regulators, such as the U.S. Food and
Drug Administration, who place a premium on objective findings [13]. Propensity scores
can be particularly useful in high-dimensional settings when event rates are low or when
the number of confounders is large relative to number of events. As a result, many in-
vestigators interested in observational causal inference with high-dimensional data have
focused on how to build propensity score models. Variable selection is the standard re-
sponse to dealing with high-dimensional data, and researchers have historically focused
on selecting important confounders based on subject matter expertise and rules of thumb
[3][35]. More algorithmic variable selection techniques have also been explored, including
the high-dimensional propensity score algorithm of Schneeweiss et al, but this uses out-
come information to select variables [28]. Other approaches have proposed more technical
variance reduction strategies through machine learning methods, such as elastic net regular-
ization, tree-based algorithms, and learning ensembles [32][15][38]. Each of these methods
has shown promise in estimating causal effects from large databases. We use a Bayesian
framework because it propagates uncertainty from the propensity score model and pro-
vides intuitive and sophisticated variance reduction strategies via prior distributions, an
advantage that we leverage through a hierarchical prior specification.
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2.2.1 Bayesian Propensity Scores
We adopt a Bayesian treatment model and maintain an outcome free analysis, although
jointly modeling the propensity score and outcomes has been proposed [16][26]. The partic-
ular algorithm we use resembles frequentist propensity score weighting [31]. The algorithm
uses a conjugate prior-likelihood pair in the form of a beta-binomial: if Y represents the
total number of subjects having an event out of n subjects, e.g., Y
iid∼ Bin(n, p), then as-
suming p arises from Beta(a, b) a-priori, yields a-posteriori p | Y ∼ Beta(a+ Y, b+ n− Y ).
We use this fact to integrate over draws from the propensity score model while condition-
ally drawing from the outcome model, so that uncertainty is incorporated from both the
propensity score model and the outcome model.
Briefly, let Yi denote binary outcome for subject i, Xi binary treatment, and pii the
propensity score, P(Xi = 1). The parameter pi is the vector of propensity scores for all sub-
jects, X is the vector of treatment indicators, Y the vector of outcomes, and D = {X,Y }
their concatenation into an n× 2 matrix. Together, pi and D are sufficient to estimate an
unbiased treatment effect under an ignorable treatment assignment mechanism. Let p1 and
p0 be the marginal probability of the event in treatment group 1 and 0 respectively. These
can be estimated in an unbiased fashion by weighting the original populations according to
the inverse of their propensity scores.
We let Y˜ (1) denote the total number of potential events in treatment group 1 (all
subjects for which Xi = 1), and Y˜ (0) the number of events in treatment group 0. By
assuming a binomial likelihood for Y˜ (1) and Y˜ (0), and selecting flat priors p0 and p1 ∼
Beta(1, 1), we can take advantage of conjugacy to get closed form solutions for the posterior
distributions for p0 and p1. The priors are augmented by weighted counts of successes and
failures in each treatment group to generate beta posteriors , pg | D,pi ∼ Beta
(
a∗g, b∗g
)
for
g = 0, 1 where
a∗g = 1 + γg
(
g
n∑
i=1
XiYi
pii
+ (1− g)
n∑
i=1
(1−Xi)Yi
1− pii
)
,
b∗g = 1 + γg
(
g
n∑
i=1
Xi(1− Yi)
pii
+ (1− g)
n∑
i=1
(1−Xi)(1− Yi)
1− pii
)
and a∗g (b∗g) describes the weighted number of events (non-events) in treatment group g. The
quantity γg is used to normalize the weighted population to its original size and is defined
as γg = g
∑n
i=1
(1−Xi)(1−Yi)
1−pii + (1− g)
∑n
i=1
(1−Xi)(1−Yi)
1−pii . The causal parameter, such as the
average treatment effect, can be calculated as simple functions of draws from the respective
posteriors of p0 and p1 - for example the average treatment effect defined by the posterior
risk difference, ∆ = p1 − p0. Estimates can be obtained using Markov Chain Monte Carlo
simulation and incorporate the uncertainty from both the propensity score and outcome
models (see in Spertus et al [31]).
3 Proposed Risk Adjustment Approaches
We now consider estimating propensity scores pii = P(Xi|Bi,Ci), where Bi is a vector of
baseline confounders, for example demographic or clinical covariates from a clinical registry,
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and Ci is a vector of 4-digit ICD-9 diagnosis codes. We use 4-digit rather than 5-digit codes
for simplicity and without loss of generality. We define the propensity score model as
pii = logit
−1{β0 + βBBi + βCCi}. (1)
The intercept β0 and coefficients associated with the baseline confounders βB are stan-
dard logistic regression parameters. We set a non-informative prior for the intercept as
β0 ∼ N (0, 10). The 95% interval for β0 is about [-20,20], which on the logit scale encom-
passes the vast majority of possible values for the marginal treatment rate. We assume
that each component of βB is distributed a priori as t5(0, 2.5) and components are mutu-
ally independent. This prior is referred to as “weakly informative” in the Bayesian data
analysis literature [10]. It places the majority of prior mass within [-5,5] though heavy
tails allow larger estimates if the data warrants. Weakly informative priors help produce a
well-defined posterior but otherwise do little shrinkage compared to a maximum likelihood
estimate. Having specified priors for the intercept and baseline variables, we turn to various
approaches to handling the claims variables Ci using regularization.
3.1 Regularization via Prior Distributions
3.1.1 Weakly Informative Prior Distributions
A natural choice for the prior distribution of βC is weakly informative such that βC ∼
t5(0, 2.5). These priors could be applied to groups of codes at the 3-digit level, or to more
granular 4-digit codes. The latter is likely to have higher variance but less bias, and we
explore both possibilities in our application. However, alternatives may be required because
it is likely that the majority of the ICD-9 codes are rare and have no relationship with the
treatment assignment, so they will introduce considerable variance.
3.1.2 Sparsity-Inducing Prior Distributions
An alternative sparsity-inducing prior is the horseshoe prior where for the jth component
of βC . We assume the associated coefficient is
βCj ∼ N (0, λ2jτ2); where λj ∼ Cauchy+(0, 1) and τ ∼ Cauchy+(0, 1). (2)
The notation Cauchy+(0, 1) denotes a half-Cauchy distribution defined over the positive
real line. The horseshoe performs global shrinkage through τ and local shrinkage through
λj , allowing signals to remain near their maximum likelihood estimates, while shrinking
noise variables aggressively towards zero. It has shown impressive predictive properties in
simulations and applied problems [5][19]. For easier sampling, we replace the priors for λj
with t+3 (0, 1) priors which users find have little effect on coefficient estimates in practice
[22].
Under this specification, 50% of the prior mass on βCj is placed between -.4 and .4,
which is quite close to zero. However the 95% prior interval is about (-11,11), reflecting
the fact that the horseshoe places a lot of prior weight near zero but also has “fat tails” in
order to avoid shrinking signals.
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3.1.3 Hierarchical Prior Distributions
As an alternative to standard weakly informative or sparsity-inducing priors, we propose
a hierarchical prior on βC that takes advantage of the natural tree-like hierarchy in ICD-9
codes. Assuming p elements for Ci, each element falls into one of L 3-digit categories,
where category l is associated with pl ≥ 1 codes. The codes in category l are denoted
by Cil. The vector of coefficients for Ci has a special structure. It is partitioned into
βC = {βC1 ,βC2 , ...βCL} where βCl is the vector of coefficients for the grouped variables
Cil. To emphasize the grouped structure in the regression, we rewrite equation 1 as:
pii = logit
−1{β0 + βBBi + L∑
l=1
pl∑
k=1
βClkCilk
}
. (3)
Capitalizing on the hierarchical structure, we define a hierarchical prior distribution as
βCl ∼ Laplace(µl, .5) where µl ∼ t5(0, 2.5). (4)
The t5(0, 2.5) priors on µl are again weakly informative. The 4-digit ICD-9 code coeffi-
cients are shrunk to the 3-digit (group) mean µl according to a Laplace distribution with
a relatively tight scale. For example, a priori each 4-digit code has a probability of 0.86
of being within 1 of the group mean coefficient µl. The choice of the Laplace distribution
over the Normal distribution forces noisier 4-digit codes to be shrunk more aggressively to
the 3-digit group mean, while fatter tails permits less shrinking of signals [10]. If there is
only one 4-digit code in a 3-digit category, then we just assume βCl = µl and specify the
weakly informative prior βCl ∼ t5(0, 2.5).
To fix ideas, imagine the group of ICD-9 codes corresponds to the category ”hypertensive
heart disease” and that it has an overall effect of µl = 2 (Figure 1). The 4-digit codes for
this category include benign, unspecified, and malignant hypertensive heart disease. We
might expect the benign condition to in fact have a small effect on stent selection such
that βCl1 = 0; the malignant form of the condition may have a larger effect than the
group mean, so βCl3 = 3; and the unspecified condition is more ambiguous and receives
an estimate equal to the group mean, βCl2 = 2. The fundamental advantage is that some
information is shared among similar conditions, while different forms and severities are able
to receive larger or smaller effect estimates as the data warrant.
3.2 Regularization via Comorbidity Scoring
Comorbidity indices are the results of a dimension reduction strategy that have the re-
lated advantages of low variance and parsimonious interpretation [11]. In typical usage,
comorbidity indices compress hundreds or thousands of binary-valued ICD-9 codes into a
smaller set of indicator variables or into a scalar summary, either of which can then be
used for prediction or risk adjustment. Either way, the resulting claims data set is much
smaller, with many of the original diagnosis data discarded or aggregated. The Elixhauser
comorbidity index, for example, reduces all ICD-9 codes into 30 indicators, which can then
be combined further into a scalar score using fixed severity weights [8][39]. The severity
weights are obtained from a regression model and are available in programs distributed
by the developer of the index. In our setting of causal inference, the association of the
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Figure 1: Hierarchical prior on ICD-9 regression coefficients. t5(0, 2.5) prior distri-
bution for µl (on top) is weakly informative for the group-level mean. βCl , the coefficients
for granular codes, are shrunk towards µl by a Laplace distribution.
Elixhauser comorbidities are nuisance parameters – their use is in meeting the ignorability
of the treatment assignment assumption.
4 Application
We implement a variety of methods to model propensity scores for DES vs BMS using the
Bayesian propensity score approach to compare inferences using a variety of regularization
strategies. We utilize ICD-9 diagnosis codes that are present-on-admission for a cohort of
adults undergoing coronary stenting in hospitals.
4.1 Claims Data and the Mass-DAC Registry
We used claims data from the Massachusetts Center for Health Information and Analy-
sis (CHIA). The CHIA data included 15 free-response fields with Present On Admission
(POA) ICD-9 codes. Because POA codes describe patients at hospital arrival, they are not
impacted by treatment decisions. To set a lower bound on sparsity we considered all 4-digit
POA ICD-9 for which 10 or more patients were coded as having the condition.
The claims data were supplemented with baseline demographic and clinical variables
from the Mass-DAC registry, a state mandated database harvesting clinical information for
all percutaneous coronary interventions (PCIs) performed in adults (age ≥ 18 years) in all
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non-Federal Massachusetts’ hospitals annually. We identified 131 potential confounders in
the Mass-DAC registry, including variables capturing demographic characteristics (e.g. age,
race), pre-existing conditions (e.g. heart disease, diabetes), or procedure information (e.g.
treated vessel, heart attack severity, hospital). The registry data are prospectively collected
by hospital personnel who use the National Cardiovascular Data Registy instrument from
the American College of Cardiology. A very small number of cells were missing data, and
we imputed a single dataset for analysis.
We compared a number of outcomes between subjects implanted with a drug elusting
stent (DES) and subjects implanted with bare metal stents (BMS) using Bayesian propen-
sity score methods: 2-day mortality, 30-day mortality, 1-year mortality, and target vessel
revascularization (TVR). Two-day and 30-day mortality are designed to serve as “falsifia-
bility endpoints.” Because any difference in the stent performance would not manifest after
such a short period, if we observe a difference on one of these outcomes it is almost certain
it is due to residual confounding. We also generally expect no difference, or a very small
difference, on 1-year mortality based on previous findings from RCTs and instrumental
variable analyses [2][42]. We do expect a significant benefit to DES on TVR rates.
4.2 Applied Methods
In all methods, the Mass-DAC variables were included and their coefficients, βB, were
specified with weakly informative t5(0, 2.5) priors. Therefore only the modeling of claims
data varied.
As baseline analyses, we fit two different Bayesian propensity score models to the log-
odds of DES based on the Elixhauser index. We first grouped variables using the mapping of
Quan et al from ICD-9 codes to the 30 original Elixhauser categories [8][23]. This mapping
was accomplished in R using the package medicalrisk [17]. We then implemented a model
with indicator variables for each category and used a weakly informative t5(0, 2.5) prior. We
refer to this model as “Elixhauser indicator.” Second, we replaced the 30 binary indicators
with a comorbidity score created by summing the product of each indicator with its fixed
severity weight.[39] We refer to this model as the “Elixhauser continuous.”
We used the full claims set (defined as all 4-digit POA ICD-9 for which 10 or more
patients were coded as having the condition) with weakly informative, sparsity-inducing,
and hierarchical priors to estimate the propensity score. As standard approaches a logistic
regression using 3-digit codes and t5(0, 2.5) priors and a logistic regression using 4-digit
ICD-9 codes and t5(0, 2.5) priors were fit [18]. Using 3-digit rather than 4-digit codes is a
typical dimension reduction technique. We have found t5(0, 2.5) priors to behave similarly
to non-informative priors (analagous to maximum likelihood estimation) in this setting,
but have slightly more posterior stability and easier sampling [10]. As an alternative, we
used horseshoe priors for strong regularization on the full 4-digit ICD-9 code set. Finally,
we place a hierarchical prior on the coefficients so that coefficients associated with 4-digit
codes are shrunk together towards the coefficients of the 3-digit codes.
The propensity score models were fit using Stan for Hamiltonian Monte Carlo sampling
from each posterior [4]. The convergence of the samplers was assessed by examining trace
plots and by the Gelman-Rubin “r-hat” statistic, where a value less than 1.1 indicated
sufficient convergence [10]. To assess the out-of-sample fit of different models, we calculated
the leave-one-out information criterion (LOO-IC). LOO-IC is an approximation to leave-
one-out cross validation that can be computed from a point-wise log-likelihood matrix
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using Pareto-smoothed importance sampling, a procedure implemented in R through the
loo package [40][41]. A lower LOO-IC indicates a model with better predictive accuracy.
To assess adjustment for measured confounders, we calculated how well the propensity
scores balanced the observed covariates by calculating standardized differences, defined as
the difference in means between the weighted BMS and DES populations over their pooled
standard deviation. Because we have a different weighted population for each propensity
score draw, this quantity is calculated once for each draw, giving a standardized difference
distribution for each variable [1]. We assess the overall balance by determining the per-
centage of covariates with posterior mean standardized difference falling within (-10,10) [1].
Ideally, the 95% intervals for standardized differences will also be contained within (-10,10)
for most variables.
We assessed how well each method met our falsifiability endpoints and their causal
effect estimates for 2-day, 30-day, and 1-year TVR. We were particularly interested in the
coverage and width of the 95% posterior intervals and whether they included zero.
4.3 Results
After eliminating diagnoses with fewer than 10 observed occurrences, we were left with a
total of 334 4-digit ICD-9 confounders. There were fewer than 10 patients with individual
codes in the “psychoses” Elixhauser category, so the Elixhauser indicator sets included 29
diagnoses rather than 30.
Grouping by the first 3-digits of the ICD-9 codes resulted in 69 groups containing at
least 2 4-digit codes and 117 single 4-digit codes with no higher level group. The condition
with the largest number of 4-digit codes in our sample was acute myocardial infarctions, i.e.
heart attacks, and contained 10 4-digit codes. Thirty-seven of the 69 groups had only 2 4-
digit codes. The complete list of all outcomes and confounders along with their prevalences
(or means and standard deviations) appears in our appendix below.
Table 1 displays characteristics of the propensity score models including number of
claims variables used, LOO-IC, and summaries of covariate balance. In terms of fit, Horse-
shoe regularization achieved the lowest LOO-IC score, indicating it had the best predictive
accuracy. The Elixhauser indicator also had good LOO-IC, achieved through a consider-
able reduction in the dimension of the regression, though further reduction into a score
degraded the quality of the fit considerably as indicated by a higher LOO-IC for Elixhauser
continuous. The hierarchical prior provided lower LOO-IC than either the 4-digit or 3-digit
t5(0, 2.5) prior approaches.
In terms of balance, the Elixhauser methods and 3-digit codes with weakly informative
priors failed to bring posterior mean standardized difference for all variables to within (-
10,10). Regressions using the full claims set with weakly informative or hierarchical priors
had many confounders for which the upper (or lower) 95% posterior interval limit is beyond
10% (or smaller than -10%) after weighting. In contrast, the confounder balance when using
a horseshoe prior results in only 6 variables with standardized difference posterior intervals
outside the 10% window.
Figure 2 illustrates the behavior of the different approaches to regularization when using
the full claims set for two groups (e.g., two 3-digit diagnosis codes): cardiac dysrhythmias
and drug/alcohol abuse. For cardiac dysrhythmias, the group mean for the hierarchical
prior coefficients is very close to zero because the associations of the individual codes have
opposite signs on the logit of the probability of receiving a DES. The hierarchical prior coef-
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Approach # Claims Variables LOO-IC (SE) Means /∈ (-10,10) CIs /∈ (-10, 10)
Unadjusted∗ 0 11327 (54) 196 NA
Elixhauser Methods
t5(0, 2.5) Prior Indicator Variables 29 9537 (94) 3 11
t5(0, 2.5) Prior Continuous Score 1 9640 (92) 4 12
Full Claims Set
t5(0, 2.5) Prior 3-Digits 186 9662 (100) 1 59
t5(0, 2.5) Prior 4-Digits 334 9741 (107) 0 150
Horseshoe Prior 4-Digits 334 9468 (88) 0 6
Hierarchical Prior 3 and 4-Digits 334 9639 (104) 0 74
Table 1: Characteristics of propensity score models. Number of claims derived
variables used in model, leave-one-out information criterion, and summaries of covariate
balance for unadjusted analysis and each propensity score analysis. Column “Means /∈
(-10,10)” tabulates the number of variables with posterior mean standardized differences
outside the interval -10 to 10, which is typically considered good balance. Column “CIs
/∈ (-10, 10)” tabulates number of variables where some part of the 95% posterior interval
lies outside (-10,10). LOO-IC = leave-one-out information criterion; SE = standard error.
∗: This is a model with an intercept only for the purpose of calculating LOO-IC and
standardized differences reflect covariates in unweighted population.
ficients are slightly pooled towards their group mean, while coefficients under the horseshoe
are pulled towards zero, in some cases quite sharply. The weakly informative coefficients are
universally larger in magnitude than the others. A similar pattern emerges for drug/alcohol
abuse coefficients. The group overall is associated with a lower probability of receiving a
DES, with some granular codes exhibiting much smaller or larger effects. For both co-
efficient groups, a weakly informative prior using a single indicator for the 3-digit code
category fails to capture the nuances apparent at lower levels.
Table 2 presents posterior summaries of causal effects in the Mass-DAC data under
each method. The unadjusted difference in means between the two stent groups exhibits
considerable confounding of both 30-day and 1-year mortality with large risk reductions
for DES of 3.4% and 6.9% respectively. The Elixhauser approaches were the only models
unable to adjust away the difference in 2-day mortality, though margins were slim. For
30-day mortality, only the full claims sets with t5(0, 2.5) or hierarchical priors estimated
no significant effect. In contrast, aggressively regularizing using horseshoe priors yielded
a 30-day mortality benefit to DES that is indicative of residual confounding. On one-year
mortality, the model utilizing the hierarchical prior distribution for the ICD-9 coefficients
achieved a considerable reduction from the large unadjusted difference, and improved over
the comparably large effect estimates generated from the Elixhauser and horseshoe prior
approaches. However no method included zero in its 95% credible interval, conflicting with
findings from randomized trials. As expected, all methods produced a larger benefit to
TVR than indicated by the unadjusted difference.
The Elixhauser indicator, Elixhauser continuous, and horseshoe approaches had the low-
est uncertainty with posterior interval widths of 1.9, 1.8, and 2.0 respectively. The weakly
informative 3-digit approach had an average width of 2.3, while the weakly informative
4-digit approach had an average of width of 3.0. The hierarchical prior approach had an
average credible interval width of 2.5, about 20% tighter than the 4-digit approach. The
weakly informative and hierarchical specifications thus incur more variance than the smaller
or more regularized Elixhauser and horseshoe approaches, which is ultimately reflected in
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Figure 2: Selected posterior mean coefficients. Values on log-odds scale for 4-digit
ICD-9 coefficients with weakly informative priors (orange circle), horseshoe (red triangle),
and hierarchical (blue diamond) specifications. Group mean defined by 3-digit code for
hierarchical (blue dashed line) and 3-digit weakly informative coefficient estimate (green
dashed line) are also shown. Left panel shows coefficients for code group 427, cardiac
dysrhythmias; right panel shows coefficients for code group 305, drug or alcohol abuse.
the estimated distributions of causal parameters.
Mortality
Approach 2-Day 30-Day 1-Year 1-Year TVR
Unadjusted -1.0 (-1.4, -0.6) -3.4 (-4.1, -2.7) -6.9 (-8.0, -5.7) -2.4 (-3.7, -1.3)
Elixhauser Methods
t5(0, 2.5) Prior Indicator Variables -0.4 (-0.7, -0.1) -1.2 (-2.0, -0.5) -3.1 (-4.3, -1.8) -4.3 (-5.7, -2.9)
t5(0, 2.5) Prior Continuous Score -0.4 (-0.7, -0.1) -1.3 (-2.0, -0.6) -3.3 (-4.5, -2.1) -4.5 (-5.9, -3.0)
Full Claims Set
t5(0, 2.5) Prior 3-Digits -0.3 (-0.7, 0.1) -1.0 (-2.0, 0.2) -2.7 (-4.1, -1.1) -4.4 (-6.1,-2.8)
t5(0, 2.5) Prior 4-Digits -0.3 (-0.7, 0.0) -0.7 (-2.0, 1.2) -2.5 (-4.5, -0.3) -3.6 (-5.5, -1.8)
Horseshoe Prior 4-Digits -0.3 (-0.7, 0.0) -1.1 (-1.9, -0.3) -3.0 (-4.3, -1.7) -4.1 (-5.6, -2.6)
Hierarchical Prior 3 and 4-Digits -0.3 (-0.7, 0.1) -0.9 (-2.0, 0.5) -2.6 (-4.2, -0.8) -3.8 (-5.5, -2.0)
Table 2: Casual effect estimates for selected outcomes. Risk differences for various
methods applied to the coronary stent study. Risk differences (95% Credible Intervals) esti-
mated from the Mass-DAC data show benefit of DES compared to BMS in terms of reduced
percent chance of given outcome (∆ = pDES−pBMS). TVR = target vessel revascularization.
5 Discussion
In this paper, we proposed the use of regularizing prior distributions rather than comorbid-
ity indices for data reduction strategies in high-dimensional causal inference problems in
health care. We found that Bayesian priors improved inferences over comorbidity indices
both in terms of out-of-sample fit or the ability to meet falsifiability endpoints. These prior
distributions are able to work with a large number of claims variables while controlling
variance.
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To compare multiple methods with and without hierarchical modeling of ICD-9 codes,
we estimated causal effects of DES compared to BMS on a number of outcomes. Specifically,
we were looking for our methods to adjust away any difference in 30-day mortality and,
ideally, 1-year mortality as well. RCTs have consistently shown no survival benefit to DES,
but this has proved to be very difficult to replicate in observational analyses [2][42][34][14].
By using claims data and either a hierarchical ICD-9 or flat weakly informative propensity
score model, we succeeded in removing the specious benefit shown to 2-day and 30-day
mortality, which were very likely to be caused by residual confounding. In contrast, models
using Elixhauser comorbidity indicators, a continuous Elixhauser score, or sparsity-inducing
horseshoe priors on the full claims set did not manage to adjust away confounding on 30-day
mortality. The fact that these dimension reducing approaches generated the best out-of-
sample fit in terms of LOO-IC indicates the importance of using additional checks like
falsifiability endpoints in causal inference problems, rather than relying solely on scores of
predictive ability.
Unfortunately no method succeeded in removing all confounding of 1-year mortality, but
the hierarchical and weakly informative prior distributions had comparably more success,
estimating small effect sizes and 95% credible intervals close to 0. Residual confounding has
plagued past observational studies of DES and BMS and it appears that, while claims data
are able to account for important confounders not found in registries, we are still lacking the
necessary variables to completely remove confounding [14]. Likely unmeasured confounders
include socio-economic variables, which past studies have shown affect adherence to dual-
antiplatelet therapy and ultimately a doctor’s decision to use a DES versus a BMS in usual
care settings [33].
While generating similar posterior means, the hierarchical prior approach had consid-
erably smaller variance than the unregularized approach, with about 20% tighter credible
intervals on average. All methods showed, as expected, a considerable benefit to DES on
the TVR outcome.
We restricted our attention to Bayesian propensity scores throughout, only changing
the variable selection or regularization strategy for comparability. However, hierarchical
ICD-9 code modeling is not limited to Bayesian propensity scores and could easily be
adapted to Bayesian outcome modeling or frequentist techniques. Whatever the specifics,
our work demonstrates that investigators performing causal inference in non-randomized
settings could benefit by ignoring comorbidity indices and using more claims variables
in their analyses. Comorbidity indices will continue to have utility for risk stratification
and parsimonious assessments in clinical practice, but as we have shown, there are better
alternatives for confounder adjustment.
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A Covariate Tables
A.1 Registry Covariates
Table 3: Prevalence or mean (SD) of outcomes in the Mass-DAC registry. “Cases per Site”
gives min, mean (SD), and max of numbers treated at the 25 hospitals, overall and in each
treatment group. The 31 coronary artery segment indicators are not shown. HMO = health
maintenance organization; CAD = coronary artery disease; CVD = cardiovascular disease;
PAD = peripheral artery disease; CABG = coronary artery bypass graft; STEMI = ST-
elevated myocardial infarction; LVSD = left ventricular systolic dysfunction; NYHA = New
York heart association; LAD = left anterior descending (artery); RCA = right coronary
artery.
Overall BMS DES
Number Treated (n) 8718 3081 5637
Registry Outcomes
% 2 Day Mortality 0.50 1.14 0.16
% 30 Day Mortality 2.01 4.19 0.82
% 1 Year TV Revascularization 7.38 8.96 6.51
% 1 Year Mortality 5.75 10.19 3.32
Registry Confounders
% Male 69.39 68.16 70.05
Mean (SD) Age in Years 64.66 (12.5) 66.37 (11.7) 63.72 (13.5)
Mean (SD) Height in cm 170.67 (10.5) 170.41 (10.6) 170.81 (10.4)
Mean (SD) Weight in kg 86.48 (20.3) 84.89 (19.9) 87.34 (20.8)
Race
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% Caucasian 91.26 90.72 91.56
% Black 3.79 4.87 3.19
% Asian 2.31 2.43 2.24
% Native American < 0.1 < 0.3 < 0.2
% Native Pacific < 0.1 < 0.3 < 0.2
% Hispanic or Latino 4.55 4.8 4.42
Payor
% Government 51.57 59.17 47.42
% None 2.56 4.12 1.7
% Non-US < 0.1 < 0.3 < 0.2
% Private Commercial or HMO 45.82 36.68 50.82
% Smoker 74.68 70.85 76.78
% Hypertension 78.3 76.6 79.23
% Dyslipidemia 81.82 77.96 83.93
% Diabetes 32.16 30.38 33.14
% Family History CAD 28.96 24.08 31.63
% Chronic Lung Disease 14.21 16.42 13
% Current Dialysis 1.82 2.21 1.61
% Prior CVD 10.23 11.33 9.63
% Prior PAD 11.96 12.76 11.53
% Prior Myocardial Infarction 26.67 25.84 27.12
% Prior Heart Failure 10.61 12.46 9.6
% Prior Valve Surgery 1.56 2.34 1.14
% Prior PCI 27.56 19.77 31.83
% Prior CABG 12.3 11.46 12.76
% Prior Cardiogenic Shock 1.9 3.89 0.82
% Prior Cardiac Arrest 2.29 4.15 1.28
CAD Presentation
% No Angina 5.32 5.78 5.07
% Symptom Unlikely to be Ischemic 1.00 1.17 0.90
% Stable Angina 11.88 5.81 15.2
% Unstable Angina 30.19 23.4 33.9
% Non-STEMI 27.23 28.17 26.72
% STEMI 24.37 35.67 18.2
% Thrombolytic Therapy 0.8 1.23 0.57
% Cardiomyopathy or LVSD 9.36 11.1 8.41
Anginal Canadian Classification
% 0 9.64 11.65 8.53
% I 2.4 1.59 2.84
% II 12.2 7.66 14.69
% III 28.83 24.15 31.38
% IV 46.94 54.95 42.56
Anti-Anginal Medications
% Beta Blockers 57.79 54.56 59.55
% Calcium Channel Blockers 11.44 11.39 11.46
% Long Acting Nitrates 11.49 9.41 12.63
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% Ranolazine 0.62 0.45 0.71
% Other Agent 1.4 1.01 1.61
NYHA Class
% 0 87.57 83.51 89.78
% I 0.91 0.78 0.98
% II 3.06 3.67 2.73
% III 4.16 5.39 3.49
% IV 4.3 6.65 3.02
% Compassionate Use 0.91 2.01 0.3
% Cardiogenic Shock 1.85 3.8 0.78
% Mechanical Ventricular Support 0.58 1.14 0.28
% Ejection Fraction < 30% 2.88 3.7 2.43
Coronary Anatomy
% Left Dominant 8.30 8.08 8.42
% Right Dominant 86.19 85.88 86.36
% Left Dominant 5.51 6.04 5.22
% Left Main Disease 5.93 6.52 5.61
Mean Left Main Stenosis (SD) 7.98 (19.8) 8.74(19.3) 7.57(20.7)
Mean Proximal LAD Stenosis (SD) 36 (39.7) 35.1(39.7) 36.5(39.5)
Mean Mid-Distal LAD Stenosis (SD) 48.2 (39.7) 47.64(39.7) 48.51(39.6)
Mean Circumflex Stenosis (SD) 47.95 (40.8) 47.94(40.7) 47.96(40.8)
Mean RCA Stenosis (SD) 60.66 (39.9) 65.25(40) 58.15(39.2)
Status
% Urgent 52.49 48.78 54.51
% Emergent 26.69 38.30 20.35
% Other 20.82 12.92 25.14
PCI Indication
% Immediate PCI for STEMI 21.80 31.39 16.55
% STEMI (Unstable, > 12 hours) 1.67 2.66 1.14
% STEMI (Stable, > 12 hours) 0.57 0.94 0.37
% STEMI (Stable, thrombolytics) 0.44 0.58 0.35
% STEMI (Rescue, failed thrombolytics) 0.46 0.75 0.3
% High risk Non-STEMI 48.99 45.86 50.7
% Staged 0.86 0.45 1.08
% Other 25.21 17.36 29.5
Mean (SD) Thrombectomies 0.12 (0.3) 0.16(0.3) 0.09(0.4)
Mean (SD) Total Stents Used 1.46 (0.8) 1.41 (0.8) 1.5 (0.8)
Mean (SD) Lesions 1.3 (0.6) 1.24 (0.6) 1.33 (0.5)
Mean (SD) Lesion Length 18.08 (10) 17 (10.4) 18.68 (9.3)
% In-stent Restenosis 6.96 2.34 9.49
% Chronic Total Occlusion 1.73 1.3 1.97
Cases per Site (25 Total)
Min # Treated 47 12 14
Mean # Treated (SD) 349 (269) 123 (99) 225 (187)
Max # Treated 896 352 605
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Table 4: Prevalence of present on admission ICD-9 diagnosis codes used in analysis. As
with the analysis using a hierarchical prior, codes are grouped together if there were two
or more 4-digit codes sharing a 3-digit grouping. w/o = without.
Diagnosis Code Description (Present on Admission) Prevalence
041 Bacterial infection of unspecified site 0.5
0411 Staphylococcus infection, unspecified 0.2
0414 Shiga toxin-producing E. coli (STEC) 0.3
070 Viral hepatitis 1.1
0703 Viral hepatitis B w/o mention of hepatic coma 0.2
0705 Acute hepatitis C w/o mention of hepatic coma 0.4
0707 Unspecified viral hepatitis C w/o hepatic coma 0.5
242 Thyrotoxicosis with or w/o goiter 0.3
2420 Toxic diffuse goiter w/o mention of thyrotoxic crisis or storm 0.1
2429 Thyrotoxicosis w/o mention of goiter, thyrotoxic crisis, or storm 0.2
244 Acquired hypothyroidism 7.4
2440 Postsurgical hypothyroidism 0.2
2448 Other specified acquired hypothyroidism 0.2
2449 Unspecified acquired hypothyroidism 7
250 Diabetes mellitus 30.8
2500 Diabetes mellitus w/o mention of complication 27
2501 Diabetes with ketoacidosis 0.2
2504 Diabetes with renal manifestations 1.5
2505 Diabetes with ophthalmic manifestations 1.1
2506 Diabetes with neurological manifestations 1.9
2507 Diabetes with peripheral circulatory disorders 0.2
2508 Diabetes with other specified manifestations 0.3
272 Disorders of lipoid metabolism 69.9
2720 Pure hypercholesterolemia 13.7
2721 Pure hyperglyceridemia 1
2722 Mixed hyperlipidemia 0.1
2724 Other and unspecified hyperlipidemia 59.4
2729 Unspecified disorder of lipoid metabolism 0.1
274 Gout 3.5
2740 Gouty arthropathy, unspecified 0.3
2749 Gout, unspecified 3.2
275 Disorders of mineral metabolism 0.9
2750 Hereditary hemochromatosis 0.1
2752 Disorders of magnesium metabolism 0.3
2753 Disorders of phosphorus metabolism 0.2
2754 Unspecified disorder of calcium metabolism 0.3
276 Disorders of fluid, electrolyte, and acid-base balance 4.5
2760 Hyperosmolality and/or hypernatremia 0.1
2761 Hyposmolality and/or hyponatremia 1.2
2762 Acidosis 0.7
2764 Mixed acid-base balance disorder 0.1
2765 Volume depletion, unspecified 0.7
20
2766 Transfusion associated circulatory overload 0.1
2767 Hyperpotassemia 0.7
2768 Hypopotassemia 1.1
280 Iron deficiency anemias 1.4
2800 Iron deficiency anemia secondary to blood loss (chronic) 0.2
2809 Iron deficiency anemia, unspecified 1.2
281 Other deficiency anemias 0.3
2810 Pernicious anemia 0.1
2819 Unspecified deficiency anemia 0.1
285 Other and unspecified anemias 5.5
2851 Acute posthemorrhagic anemia 0.1
2852 Anemia in chronic kidney disease 1.5
2858 Other specified anemias 0.1
2859 Anemia, unspecified 3.8
287 Purpura and other hemorrhagic conditions 1.3
2874 Posttransfusion purpura 0.1
2875 Thrombocytopenia, unspecified 1.2
294 Other organic psychotic conditions (chronic) 1
2941 Dementia w/o behavioral disturbance 0.2
2948 Other persistent mental disorders 0.8
296 Affective psychoses 1.4
2962 Major depressive affective disorder, single episode 0.2
2963 Major depressive affective disorder, recurrent episode 0.1
2968 Bipolar disorder, unspecified 0.9
2969 Unspecified episodic mood disorder 0.1
300 Neurotic disorders 6.8
3000 Anxiety state, unspecified 4.6
3004 Dysthymic disorder 2.2
305 Nondependent abuse of drugs 21.9
3050 Alcohol abuse, unspecified 2.2
3051 Tobacco use disorder 20.4
3052 Cannabis abuse, unspecified 0.9
3055 Opioid abuse, unspecified 0.2
3056 Cocaine abuse, unspecified 0.7
3059 Other, mixed, or unspecified drug abuse, unspecified 0.2
333 Extrapyramidal disease and abnormal movement disorders 0.6
3331 Essential and other specified forms of tremor 0.2
3339 Unspecified extrapyramidal disease and abnormal movement 0.4
338 Pain, not elsewhere classified 2
3382 Chronic pain due to trauma 1.8
3384 Chronic pain syndrome 0.2
348 Other conditions of brain 0.5
3481 Anoxic brain damage 0.4
3483 Encephalopathy, unspecified 0.1
355 Mononeuritis of lower limb 0.4
3558 Mononeuritis of lower limb, unspecified 0.1
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3559 Mononeuritis of unspecified site 0.3
362 Other retinal disorders 1.4
3620 Background diabetic retinopathy 1
3625 Macular degeneration (senile), unspecified 0.4
396 Diseases of mitral and aortic valves 0.7
3962 Mitral valve insufficiency and aortic valve stenosis 0.3
3963 Mitral valve insufficiency and aortic valve insufficiency 0.3
401 Essential hypertension 62.4
4010 Malignant essential hypertension 0.1
4011 Benign essential hypertension 0.7
4019 Unspecified essential hypertension 61.6
410 Acute myocardial infarction 54.3
4100 AMI of anterolateral wall 2.7
4101 AMI of other anterior wall 6.4
4102 AMI of inferolateral wall 2.2
4103 AMI of inferoposterior wall 2.4
4104 AMI of other inferior wall 9.5
4105 AMI of other lateral wall 0.9
4106 True posterior wall infarction 0.2
4107 Subendocardial infarction 28.7
4108 AMI of other specified sites 0.3
4109 AMI of unspecified site 1.1
411 Other acute and subacute form of ischemic heart disease 19.8
4111 Intermediate coronary syndrome 19.3
4118 Acute coronary occlusion w/o myocardial infarction 0.5
414 Other forms of chronic ischemic heart disease 86.7
4140 Coronary atherosclerosis of unspecified vessel 85.6
4141 Aneurysm of heart (wall) 0.6
4142 Chronic total occlusion of coronary artery 9.5
4148 Other specified forms of chronic ischemic heart disease 4.9
4149 Chronic ischemic heart disease, unspecified 0.2
424 Other diseases of endocardium 6.3
4240 Mitral valve disorders 3.5
4241 Aortic valve disorders 2.8
425 Cardiomyopathy 2.6
4254 Other primary cardiomyopathies 2.5
4255 Alcoholic cardiomyopathy 0.1
426 Conduction disorders 5.2
4260 Atrioventricular block, complete 0.8
4261 Atrioventricular block, unspecified 1.3
4262 Left bundle branch hemiblock 0.1
4263 Other left bundle branch block 1.4
4264 Right bundle branch block 1.5
4265 Bundle branch block, unspecified 0.4
427 Cardiac dysrhythmias 17.3
4270 Paroxysmal supraventricular tachycardia 0.2
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4271 Paroxysmal ventricular tachycardia 2.4
4273 Atrial fibrillation 10
4274 Ventricular fibrillation 1.6
4275 Cardiac arrest 1.3
4276 Premature beats, unspecified 0.7
4278 Sinoatrial node dysfunction 4.3
428 Heart failure 15.5
4280 Congestive heart failure, unspecified 14.5
4282 Systolic heart failure, unspecified 5.6
4283 Diastolic heart failure, unspecified 3
4284 Combined systolic and diastolic heart failure, unspecified 1.6
429 Ill-defined descriptions and complications of heart disease 1.8
4293 Cardiomegaly 0.7
4298 Other disorders of papillary muscle 0.2
4299 Heart disease, unspecified 0.9
433 Occlusion and stenosis of precerebral arteries 1.8
4331 Occlusion/stenosis of carotid artery 1.8
4333 Occlusion/stenosis of multiple precerebral arteries 0.5
440 Atherosclerosis 2.6
4400 Atherosclerosis of aorta 0.3
4401 Atherosclerosis of renal artery 0.4
4402 Atherosclerosis of native arteries of the extremities 1.9
4408 Atherosclerosis of other specified arteries 0.2
441 Aortic aneurysm and dissection 1.2
4412 Thoracic aneurysm w/o mention of rupture 0.1
4414 Abdominal aneurysm w/o mention of rupture 1.1
443 Other peripheral vascular disease 5.6
4430 Raynaud’s syndrome 0.3
4438 Peripheral angiopathy in diseases classified elsewhere 0.3
4439 Peripheral vascular disease, unspecified 5
444 Arterial embolism and thrombosis 0.2
4442 Arterial embolism and thrombosis of upper extremity 0.1
4448 Embolism and thrombosis of iliac artery 0.1
447 Other disorders of arteries and arterioles 0.5
4471 Stricture of artery 0.4
4477 Aortic ectasia, unspecified site 0.1
458 Hypotension 1.7
4580 Orthostatic hypotension 0.2
4582 Hypotension of hemodialysis 0.1
4588 Other specified hypotension 0.6
4589 Hypotension, unspecified 0.7
493 Asthma 4.9
4932 Chronic obstructive asthma, unspecified 1.4
4939 Asthma,unspecified type, unspecified 3.6
518 Other diseases of lung 3
5180 Pulmonary collapse 0.4
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5184 Acute edema of lung, unspecified 0.1
5188 Acute respiratory failure 2.5
530 Diseases of esophagus 17.3
5301 Esophagitis, unspecified 0.3
5308 Esophageal reflux 17.1
536 Disorders of function of stomach 0.3
5363 Gastroparesis 0.1
5368 Dyspepsia and other specified disorders of function of stomach 0.2
564 Functional digestive disorders, not elsewhere classified 1.3
5640 Constipation, unspecified 0.8
5641 Irritable bowel syndrome 0.6
571 Chronic liver disease and cirrhosis 0.6
5715 Cirrhosis of liver w/o mention of alcohol 0.2
5718 Other chronic nonalcoholic liver disease 0.4
578 Gastrointestinal hemorrhage 0.4
5781 Blood in stool 0.1
5789 Hemorrhage of gastrointestinal tract, unspecified 0.2
584 Acute renal failure 2.8
5845 Acute kidney failure with lesion of tubular necrosis 0.3
5849 Acute kidney failure, unspecified 2.5
585 Chronic renal failure 9.9
5852 Chronic kidney disease, Stage II (mild) 0.4
5853 Chronic kidney disease, Stage III (moderate) 1.9
5854 Chronic kidney disease, Stage IV (severe) 0.6
5855 Chronic kidney disease, Stage V 0.2
5856 End stage renal disease 1.8
5859 Chronic kidney disease, unspecified 5.1
599 Other disorders of urethra and urinary tract 1.9
5990 Urinary tract infection, site not specified 1.5
5996 Urinary obstruction, unspecified 0.1
5997 Hematuria, unspecified 0.3
696 Psoriasis and similar disorders 0.8
6960 Psoriatic arthropathy 0.2
6961 Other psoriasis 0.6
707 Chronic ulcer of skin 0.8
7070 Pressure ulcer, unspecified site 0.3
7071 Ulcer of lower limb, unspecified 0.5
7072 Pressure ulcer, unspecified stage 0.3
710 Diffuse diseases of connective tissue 0.4
7100 Systemic lupus erythematosus 0.2
7101 Systemic sclerosis 0.2
715 Osteoarthrosis and allied disorders 4
7153 Osteoarthrosis, localized 0.8
7159 Osteoarthrosis, unspecified 3.2
721 Spondylosis and allied disorders 0.7
7210 Cervical spondylosis w/o myelopathy 0.2
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7213 Lumbosacral spondylosis w/o myelopathy 0.3
7219 Spondylosis of unspecified site, w/o mention of myelopathy 0.2
722 Intervertebral disc disorders 0.2
7221 Displacement of lumbar intervertebral disc w/o myelopathy 0.1
7225 Degeneration of thoracic or thoracolumbar intervertebral disc 0.1
723 Other disorders of cervical region 0.3
7231 Cervicalgia 0.2
7234 Brachial neuritis or radiculitis NOS 0.1
724 Other and unspecified disorders of back 3.4
7240 Spinal stenosis, unspecified region 0.9
7242 Lumbago 1.1
7243 Sciatica 0.2
7245 Backache, unspecified 1.3
729 Other disorders of soft tissues 1.3
7291 Myalgia and myositis, unspecified 0.8
7295 Pain in limb 0.1
7298 Swelling of limb 0.4
733 Other disorders of bone and cartilage 2.1
7330 Osteoporosis, unspecified 1.7
7339 Disorder of bone and cartilage, unspecified 0.4
780 General symptoms 3.5
7800 Coma 0.2
7802 Syncope and collapse 0.7
7803 Febrile convulsions (simple), unspecified 0.2
7804 Dizziness and giddiness 0.4
7805 Sleep disturbance, unspecified 1.4
7806 Fever, unspecified 0.3
7807 Chronic fatigue syndrome 0.2
7809 Fussy infant (baby) 0.3
785 Symptoms involving cardiovascular system 2.4
7850 Tachycardia, unspecified 0.2
7852 Undiagnosed cardiac murmurs 0.3
7855 Shock, unspecified 2
786 Symptoms involving chest or respiratory system 1.5
7860 Respiratory abnormality, unspecified 0.6
7862 Cough 0.1
7863 Hemoptysis 0.1
7865 Chest pain, unspecified 0.7
787 Symptoms involving digestive system 0.8
7870 Nausea with vomiting 0.2
7872 Dysphagia, unspecified 0.3
7879 Diarrhea 0.3
788 Symptoms involving urinary system 0.7
7882 Retention of urine, unspecified 0.3
7883 Urinary incontinence, unspecified 0.3
7884 Urinary frequency 0.1
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790 Nonspecific findings on examination of blood 2.4
7902 Impaired fasting glucose 1.8
7904 Elevation of levels of transaminase or LDH 0.2
7906 Other abnormal blood chemistry 0.1
7909 Abnormal arterial blood gases 0.3
794 Nonspecific abnormal results of function studies 1.4
7943 Abnormal cardiovascular function study, unspecified 1.2
7948 Nonspecific abnormal results of function study of liver 0.2
996 Complications peculiar to certain specified procedures 5
9967 Other complications due to unspecified device, implant, and graft 4.8
9968 Complications of transplanted organ, unspecified 0.2
E87 0.5
E878 Transplant of whole organ causing abnormal reaction or complication 0.4
E879 Cardiac catheterization as the cause of reaction or complication 0.1
2780 Obesity, unspecified 12.3
4039 Hypertensive chronic kidney disease 9.1
4139 Other and unspecified angina pectoris 7.9
496 Chronic airway obstruction, unspecified 7.3
3272 Organic sleep apnea, unspecified 4.9
6000 Hypertrophy of prostate without urinary obstruction 4.9
311 Depressive disorder, unspecified 4.8
4168 Other chronic pulmonary heart diseases 1.9
3572 Polyneuropathy in diabetes 1.8
7140 Rheumatoid arthritis 1.5
7169 Arthropathy, unspecified, site unspecified 1.5
3659 Unspecified glaucoma 1.4
486 Pneumonia, organism unspecified 1.3
5621 Diverticulosis of colon 1.2
3970 Diseases of tricuspid valve 1.2
4912 Obstructive chronic bronchitis without exacerbation 1.1
2886 Leukocytosis, unspecified 1.1
3459 Epilepsy 1.1
5533 Diaphragmatic hernia 0.9
3569 Unspecified peripheral neuropathy 0.9
3039 Alcohol dependence 0.9
V498 Asymptomatic postmenopausal status 0.8
2689 Vitamin D deficiency 0.8
3469 Migraine 0.8
5838 Nephritis and nephropathy 0.8
4598 Venous insufficiency 0.7
5939 Unspecified disorder of kidney and ureter 0.7
4928 Other emphysema 0.7
7194 Pain in joint 0.6
515 Postinflammatory pulmonary fibrosis 0.6
3899 Unspecified hearing loss 0.6
185 Malignant neoplasm of prostate 0.5
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2777 Dysmetabolic syndrome 0.5
725 Polymyalgia rheumatica 0.5
3098 Posttraumatic stress disorder 0.5
6078 Balanitis xerotica obliterans 0.4
5119 Unspecified pleural effusion 0.4
3320 Paralysis agitans 0.4
2662 Other B-complex deficiencies 0.4
2898 Primary hypercoagulable state 0.4
3694 Legal blindness, as defined in U.S.A. 0.4
7990 Asphyxia 0.4
9981 Hemorrhage complicating a procedure 0.4
4029 Hypertensive heart disease without heart failure 0.4
5569 Ulcerative colitis 0.4
412 Old myocardial infarction 0.4
5070 Pneumonitis due to inhalation of food or vomitus 0.4
7840 Headache 0.3
7823 Edema 0.3
5559 Regional enteritis of unspecified site 0.3
V08 Asymptomatic human immunodeficiency virus 0.3
3669 Unspecified cataract 0.3
9971 Cardiac complications, not elsewhere classified 0.3
5355 Gastritis and gastroduodenitis 0.3
5888 Secondary hyperparathyroidism 0.3
V458 Aortocoronary bypass status 0.3
2041 Chronic lymphoid leukemia 0.3
4779 Allergic rhinitis 0.3
E849 Home accidents 0.3
2028 Other malignant lymphomas 0.2
2520 Hyperparathyroidism 0.2
5965 Hypertonicity of bladder 0.2
2387 Essential thrombocythemia 0.2
3310 Alzheimer’s disease 0.2
4239 Disease of pericardium 0.2
3140 Attention deficit disorder without mention of hyperactivity 0.2
5339 Peptic ulcer of unspecified site 0.2
6929 Contact dermatitis and other eczema 0.2
5920 Calculus of kidney 0.2
9959 Systemic inflammatory response syndrome 0.2
135 Sarcoidosis 0.2
2918 Alcohol withdrawal 0.2
340 Malignant neoplasm of right main bronchus 0.2
6826 Cellulitis and abscess of leg, except foot 0.2
7890 Abdominal pain 0.2
042 Human immunodeficiency virus 0.2
4049 Hypertensive heart and chronic kidney disease, unspecified 0.2
4465 Giant cell arteritis 0.2
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7288 Interstitial myositis 0.2
4824 Pneumonia due to Staphylococcus, unspecified 0.2
2410 Nontoxic uninodular goiter 0.2
0389 Unspecified septicemia 0.1
2841 Antineoplastic chemotherapy induced pancytopenia 0.1
2959 Unspecified schizophrenia, unspecified 0.1
3040 Opioid type dependence, unspecified 0.1
3540 Carpal tunnel syndrome 0.1
570 Acute necrosis of liver 0.1
0084 Intestinal infection due to staphylococcus 0.1
1629 Malignant neoplasm of bronchus and lung 0.1
1985 Secondary malignant neoplasm of bone and marrow 0.1
2030 Multiple myeloma 0.1
4739 Unspecified sinusitis (chronic) 0.1
501 Asbestosis 0.1
5589 Noninfectious gastroenteritis and colitis 0.1
5771 Chronic pancreatitis 0.1
5790 Celiac disease 0.1
7832 Loss of weight 0.1
1889 Malignant neoplasm of bladder 0.1
2019 Hodgkin’s disease 0.1
2536 Other disorders of neurohypophysis 0.1
2554 Glucocorticoid deficiency 0.1
2713 Intestinal disaccharidase deficiencies and malabsorption 0.1
2904 Vascular dementia, uncomplicated 0.1
3860 Meniere’s disease 0.1
4059 Unspecified renovascular hypertension 0.1
4151 Iatrogenic pulmonary embolism and infarction 0.1
490 Bronchitis, acute/chronic unspecified 0.1
6953 Rosacea 0.1
2113 Benign neoplasm of colon 0.1
3429 Hemiplegia affecting unspecified side 0.1
4370 Cerebral atherosclerosis 0.1
5742 Calculus of gallbladder 0.1
591 Hydronephrosis 0.1
7367 Deformity of ankle and foot, acquired 0.1
7812 Abnormality of gait 0.1
V125 History of unspecified circulatory disease 0.1
V158 History of failed moderate sedation 0.1
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